Novel interleukin 4 immunoconjugates
OwnerMattia Matasci, Francesca Pretto +1inventors
InventorsMattia Matasci, Francesca Pretto, Sarah Wulhfard
Life of this patent
Estimating the term…
Abstract
This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the A1 domain of tenascin C or the ED-A or ED-B isoforms of fibronectin. The antibody molecules may be positioned at the N and C terminals of the IL4. The immunoconjugate may be useful in the treatment of cancer, inflammatory autoimmune disease and other disease characterised by expression of an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling.
Claims37
A conjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling,
- wherein the N terminus of IL4 is conjugated to a first antibody molecule and the C terminus of IL4 is conjugated to a second antibody molecule.
4-6. (canceled)
10-12. (canceled)
17-19. (canceled)
(canceled)
(canceled)
(canceled)
28-30. (canceled)
A conjugate according to 7 comprising the amino acid sequence of SEQ ID NOs 35-36.
(canceled)
36-42. (canceled)
45-50. (canceled)
A method according to claim 46 wherein the disease is cancer.
Dependencies are inferred from the claim text.